Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00326885 · ClinicalTrials.gov registry record · Phase 2
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
A Phase 2 study of Malignant Ascites, sponsored by Neovii Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 18
- Study locations
NCT00326885 is a Phase 2 study of Malignant Ascites that has completed, run by Neovii Biotech. The registered enrollment target is 32 participants. The trial reports 18 study locations across 15 states.
The verdict
NCT00326885, a Phase 2 study of Malignant Ascites, has completed, sponsored by Neovii Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to determine whether the investigational drug catumaxomab is a safe and effective treatment for recurrent symptomatic malignant ascites.
Conditions Studied
Interventions
- DRUG catumaxomab
Study Locations (18)
California
- University of San Diego - La Jolla
- Stanford University Hospital and Clinics - Stanford
Florida
- University of Miami - Miami
- Florida Hospital Cancer Center - Orlando
Massachusetts
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Arizona
- University of Arizona Cancer Center - Tucson
Indiana
- Northern Indiana Cancer Research Consortium - South Bend
Kentucky
- University of Louisville Cancer Center - Louisville
Maryland
- Johns Hopkins Medical Institute - Baltimore
Michigan
- Wayne State University - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-06 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00326885
The ClinicalTrials.gov registry entry for NCT00326885 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neovii Biotech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Ascites appearing as the primary indexed condition, and to 1 intervention - of which catumaxomab is the first listed.
NCT00326885 reports 18 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00326885 about?
NCT00326885 is a clinical study titled "Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites". The purpose of this study is to determine whether the investigational drug catumaxomab is a safe and effective treatment for recurrent symptomatic malignant ascites.
What is the current status of trial NCT00326885?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2006-06. Estimated completion is 2010-08.
What conditions does trial NCT00326885 study?
This clinical trial studies the following conditions: Malignant Ascites.
What interventions are being tested in trial NCT00326885?
The interventions under investigation include: catumaxomab (DRUG).
Who is sponsoring clinical trial NCT00326885?
This trial is sponsored by Neovii Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00326885 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Ascites
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.